Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial-论文-万方医学网

Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial

导出原文传递

翻译打印收藏纠错

作者： Maghbooli, Zhila ^[1] ; Sahraian, Mohammad Ali ^[2] ; Jamalimoghadamsiahkali, Saeidreza ^[3] ; Asadi, Asma ^[4] ; Zarei, Azadeh ^[5] ; Zendehdel, Abolfazl ^[6] ; Varzandi, Tarlan ; Mohammadnabi, Sara ; Alijani, Neda ; Karimi, Mehrdad ; Shirvani, Arash ; Holick, Michael F.

作者单位： Multiple Sclerosis Res Ctr,Univ Tehran Med Sci ^[1] Ziaeian Hosp,Univ Tehran Med Sci ^[2] Shohada Pakdasht Hosp,Shahid Beheshti Univ Med Sci ^[3] Sch Persian Med,Univ Tehran Med Sci ^[4] Shariati Hosp,Univ Tehran Med Sci ^[5] Sch Med,Boston Univ ^[6]

关键词 COVID-19 25-hydroxyvitamin D 3 viral infection supplementation lymphocyte vitamin D deficiency VITAMIN-D

发布时间 2022-09-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除